The present disclosure provides a method for treating and/or preventing nephrotic syndrome, such as but not limited to MCD and MN, and conditions related to nephrotic syndrome, such as but not limited to, proteinuria and edema, as well as diabetic nephropathy, diabetes mellitus, lupus nephritis or primary glomerular disease. The present disclosure further provides methods for reducing proteinuria and other disease states as discussed herein. Such methods comprise the therapeutic delivery of an Angptl4 polypeptide or Angptl4 polypeptide derivative to a subject.In particular the disclosure relates to use of an Angptl4 polypeptide in the manufacture of a medicament for a disorder that causes nephrotic syndrome or a symptom of nephrotic syndrome. Suitably the disorder is primary glomerular disease.
